Certification Rates: a closed unit’s experience

With the advent of the New Mental Health Care Bill (July 2002), hospitals all over Gauteng have been designated as centres for 72-hour assessments.\(^1\) With the emphasis on human rights, the new act states that patients should be treated in the least restrictive environment possible, with “certification” being the last resort. Hence, all mentally ill patients who require treatment involuntarily will initially be admitted to a facility for 72 hours prior to a decision being made as to discharge, or continued treatment involuntarily. According to the new act, patients—or “mental health care users”—can be admitted voluntarily (section 25), as assisted users (section 27) or involuntarily for an initial 72 hour assessment period (section 33) and, depending on the outcome of this period, for further involuntary care (section 34).\(^1\)

Tara, The H Moross Centre will not be one of these hospitals offering 72-hour assessments although it is a designated specialised psychiatric hospital, catering for the needs of those mentally ill patients requiring tertiary assessment and longer-term care. Partly to minimise certifications, a closed unit (ward 7) was established at the hospital in 1996. In addition to 30 beds, it also has 6 seclusion rooms, and can therefore house patients who have severe psychopathology requiring containment and/or seclusion.

Certification rates 5 years before and 5 years after (1991-2000 inclusive) the opening of the unit were reviewed retrospectively. Certification rates were calculated according to the number of patients certified relative to the number of admissions to the hospital per year. The demographic profile and diagnosis of certified patients was determined.

During the 10-year period (Table I, Figure 1) under review, certification rates were generally low. Patients certified during either time period were predominantly in the 14–35 year age group with a fairly even gender distribution over the entire period (Figure 2). Chi square analyses revealed no significant difference between those certified before or after 1996 in terms of either age or gender. The most common diagnoses associated with certification were bipolar disorder, manic phase and schizophrenia. Substance abuse was a common comorbid diagnosis throughout the period of study. There were no significant differences (chi square analysis) between the two groups (pre/post 1996). The diagnoses of the uncertified population was not determined hence no comparison could be made in this regard. This holds for both age and gender as well.

As this was a retrospective study, accuracy of reported data may be questionable. Data on those patients who were not certified was not obtained. This would have assisted in establishing differences (clinically and otherwise) between those who were certified and those who were not. While certification rates were generally low, they seemed to decline further following the opening of the closed ward. The higher certification rates in 1994 and 1995 compared with the rest of the years is glaringly obvious. One can speculate as to the reasons for this. In needs to be borne in mind that this was a special time in the political history of our country, with the first demographic elections being held in 1994.

The closed unit caters for the needs of uncontained psychiatric patients who might otherwise require certification. Aggressive psychotic and manic patients, as well as suicidal patients and those requiring behavioural programmes such as severe eating disorders or personality disorders have been successfully treated in the unit. This study revealed that young adults with a diagnosis of bipolar disorder, (manic phase) appear to be a group at risk for certification. Under the new MHC Act, Tara will continue to provide care for patients who are admitted voluntarily, or as assisted patients.\(^1\)

The implications of the data suggest that, should voluntary or assisted care patients become uncontained and require further containment, the milieu of a closed unit is generally conducive to
their continued care. Such patients may then not require be trans-
fer to a different facility to continue their psychiatric treatment,
involuntarily.

Ugash Subramaney
Division of Psychiatry, Department of Neurosciences,
University of the Witwatersrand, Johannesburg, South Africa
Email: ugashs@absamail.co.za

References
1. Mental Health Care Act no 17 of July 2002. Government Gazette, Re-
South Africa, no 4627, March 1975
3. American Psychiatric Association Diagnostic and Statistical Manual of
Mental Disorders, fourth edition. Washington DC: American Psychiatric
Association; 1995.

The Vienna School of Clinical Research (VSCR)

I need to share my experience of the above institution, which was
introduced to me coincidentally during discussions with an official
from a pharmaceutical company. I was offered a brochure of the
School, visited its website, and the rest is history.

The VSCR, based in Vienna, Austria, is a non-profit educational
organization dedicated to improve clinical research and the appli-
cation of its outcomes to evidence-based health care. The School
achieves this by offering continuing education to professionals and
clinicians to ensure high scientific standards in the generation and
interpretation of clinical trial data and their application to clinical
practice. It offers scholarships to applicants from developing coun-
tries on a merit basis. These are sponsored by the city of Vienna, the
Austrian Ministry of Education, Science and Culture as well as by
other public and private organizations.

The School has fully-based its activities on academic grounds.
Close partnerships have been established with a number of renowned
universities in Europe, the Middle East, Africa and the Americas.

The educational programme consists of a range of courses, work-
shop and therapeutic area seminars tailored to physicians/investi-
gators and other hospital- and industry-based personnel involved in
clinical research. They range from 3 – 6 days in length, end with a
multiple-choice examination and are acknowledged within national
and international programmes for continuing education. Though
all the courses can be booked individually, completing a predeter-
mined number of courses and workshops can lead to the acquisi-
tion of a VSCR diploma (basic and advanced level) for certification
of special experience in clinical research.

The School does have an admission criteria, a limit to the num-
bers admitted per module, selection criteria for scholarships, and
accreditation processes. More information is available on the
School’s website: www.vscr.at.

I have been fortunate to receive a scholarship from the School to
do some courses in 2004/2005. I am following the Health Outcomes
Research stream, and have so far done 2 of the 3 Modules required
for the basic diploma. The last Module is coming up next Septem-
ber. I felt unfairly privileged when I realized I was not only the only
African by race, but also the only delegate from the African conti-
ent. When I raised this concern I learned to my amazement that
the School has not had applications from the African continent.
Now judging from the number of clinical trials being done in this coun-
try, let alone the continent, I feel a responsibility to popularize this
resource, which I think a lot of professionals in this country should
benefit from.

Edith Madela-Mntla
Deputy Director, Directorate Mental Health and Substance Abuse,
Pretoria, South Africa
Email: madele@health.gov.za

Pfizer Laboratories Launches GEODON"

Pfizer Laboratories takes pleasure in announcing the launch of GEODON”, a new atypical antipsychotic for the treatment of schizophrenia.

GEODON” has a unique combination of pharmacological activities, and demonstrates:

• Predictable efficacy against both positive and negative symptoms in schizophrenia.
• Improvement of cognitive dysfunction and affective symptoms
• Favourable tolerability and a healthy metabolic profile

Switching to GEODON” from currently available antipsychotic agents results in improvements in both positive and negative symptoms as well as improvements in symptoms of social impairment and cognition. Switching to GEODON” also results in a significant reduction in weight and lipid levels, two important tolerabil-
ity concerns with antipsychotic therapy.

GEODON” is available as GEODON® IM (ziprasidone mesylate) for intramuscular injection and in an oral formulation, GEODON® Capsules (ziprasidone HCl). The flexible dosage formulations, including 20 mg/ml IM injection and 20, 40, 60 and 80 mg capsules, facilitate the acute treatment of schizophrenia and the
transition to long-term therapy whilst allowing a pharmacological continuum.

GEODON, IM for Injection and GEODON® Capsules are available through Kinesis Logistics.

References available on request

For further information regarding GEODON®, contact Karin Keenan, GEODON” Brand Manager on Tel: 011-320 6000.